STOCK TITAN

Evolv Technologies Holdings, Inc. (EVLV) SEC Filings, Feb-Mar 2026

EVLV NASDAQ

Evolv Technologies Holdings, Inc. filings document the public-company disclosures of an AI-based security screening business with Class A common stock and warrants listed on Nasdaq. Its Form 8-K reports include financial-results releases, Regulation FD disclosures, board and officer changes, stockholder meeting results, credit-agreement disclosures and registration-statement amendments tied to resale securities and warrant exercises.

Proxy materials describe director elections, executive compensation, auditor ratification, board committee matters and shareholder voting procedures. The filings also identify capital-structure elements, including Class A common stock, warrants and subsidiary borrowing arrangements, alongside governance and reporting matters for Evolv’s screening technology operations.

Rhea-AI Summary

Evolv Technologies Holdings, Inc. director Michael Ellenbogen reported an open-market sale of 91,771 shares of Class A common stock at a weighted average price of $5.10 per share. The sale was made under a Rule 10b5-1 trading plan entered into on June 12, 2025.

The footnotes state that individual trades occurred between $5.04 and $5.17. After this sale, Ellenbogen directly owned 2,083,961 shares, and separately had 151,135 shares held indirectly through the Family Horizon Trust as a reported holding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
insider
-
Rhea-AI Summary

EVLV filed a Form 144 notifying a proposed sale of Class A Common stock. The notice lists 161,490 shares tied to a stock option exercise (cash) dated 03/06/2026 and 91,771 shares from restricted stock vesting dated 03/01/2026. The filing also reports past sales by Michael P. Ellenbogen: 80,745 shares on each of 12/15/2025, 01/16/2026, and 02/17/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Kedzierski John reported acquisition or exercise transactions in this Form 4 filing.

Evolv Technologies Holdings President & CEO John Kedzierski received a grant of 373,831 Restricted Stock Units, each representing one share of Class A common stock at no cash cost. The RSUs vest in three equal annual installments beginning on March 2, 2027, and have no expiration date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Marshall Robert E reported acquisition or exercise transactions in this Form 4 filing.

Evolv Technologies Holdings, Inc. reported that Chief Revenue Officer Robert E. Marshall received a grant of 186,915 Restricted Stock Units on March 2, 2026. Each RSU represents a contingent right to receive one share of Class A common stock. The award vests in three equal annual installments starting on March 2, 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Kutsor George C reported acquisition or exercise transactions in this Form 4 filing.

Evolv Technologies Holdings, Inc. reported that Chief Financial Officer George C. Kutsor received an equity award of 186,915 Restricted Stock Units (RSUs) on March 2, 2026. Each RSU represents a contingent right to receive one share of Class A common stock and has no expiration date.

The RSUs were granted at no cash cost and will vest in three equal annual installments starting on March 2, 2027, tying the CFO’s compensation to the company’s long-term performance and continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Evolv Technologies Holdings director Michael Ellenbogen reported both RSU vesting and a small share sale. He sold 82,913 shares of Class A common stock in an open-market transaction at a weighted average price of $5.19 per share, with individual trades ranging from $5.19 to $5.29, solely to cover withholding taxes owed on vesting RSUs.

On the prior day, he exercised and converted 66,787, 57,392 and 50,505 Restricted Stock Units into the same number of Class A shares at no cost, reflecting scheduled vesting of RSU awards. Each RSU represents one share and has no expiration, vesting in three equal annual installments beginning on March 1 of 2024, 2025 and 2026, respectively.

After these transactions, Ellenbogen directly owns 2,175,732 shares of Evolv Class A common stock and also reports indirect ownership of 151,135 shares held by the Family Horizon Trust.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
insider
Rhea-AI Summary

Evolv Technologies Holdings founder and Chief Growth Officer Anil Chitkara reported multiple equity transactions. He received a grant of 46,728 Restricted Stock Units (RSUs) on March 2, 2026, which vest in three equal annual installments commencing on March 2, 2027.

On March 1, 2026, he exercised several RSU awards, converting 53,430, 45,913 and 37,878 RSUs into an equal number of Class A common shares at no cost. He then sold 63,670 Class A shares at a weighted average price of $5.19 per share, in transactions ranging from $5.19 to $5.30.

According to the disclosure, this sale was effected solely to cover withholding taxes related to RSU vesting. After the transactions, he directly owned 1,348,651 Class A common shares and continued to hold additional unvested RSUs subject to multi-year vesting schedules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
insider
-
Rhea-AI Summary

Evolv Technologies Holdings, Inc. reported that director Henrik Kuhl acquired 9,291 restricted stock units (RSUs) as a grant. Each RSU represents a contingent right to receive one share of Class A common stock and has no expiration date.

The RSUs will vest in full at the earlier of June 20, 2026 or the day immediately before the company’s next annual meeting. Following this grant, Kuhl holds a total of 9,291 RSUs directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Evolv Technologies Holdings, Inc. director Henrik Kuhl filed an initial insider ownership report on Form 3. This filing establishes his status as a director and formally records his position as an insider, but it does not report any share purchases, sales, or other transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Evolv Technologies Holdings, Inc. director Michael Ellenbogen exercised a stock option for 80,745 shares on February 17, 2026, converting options at an exercise price of $0.24 per share into Class A common stock. The same day, he sold 80,745 Class A shares in an open-market transaction at a weighted average price of $5.47 per share, with individual trades ranging from $5.39 to $5.65, under a pre-arranged Rule 10b5-1 trading plan entered into on June 12, 2025. Following these transactions, he directly owned 2,083,961 Class A shares and indirectly held 151,135 shares through Family Horizon Trust.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

How many Evolv Technologies Holdings (EVLV) SEC filings are available on StockTitan?

StockTitan tracks 84 SEC filings for Evolv Technologies Holdings (EVLV), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Evolv Technologies Holdings (EVLV)?

The most recent SEC filing for Evolv Technologies Holdings (EVLV) was filed on March 9, 2026.